ASLAN Pharmaceuticals announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, in Clinical Immunology, a bimonthly peer-reviewed journal, supporting eblasakimab’s potential as a novel, differentiated treatment for atopic dermatitis. The publication, titled “Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers.” “We are excited about the publication of this data from our earlier Phase 1a study of eblasakimab in a high impact journal. The results show that eblasakimab appears to completely block IL-13Ralpha1 and inhibit activation of STAT6 which is responsible for driving expression of many inflammatory effector molecules,” said Dr Ferda Cevikbas, Head Translational Sciences, ASLAN Pharmaceuticals. “This, together with other data we have recently generated, suggests eblasakimab has the potential to be differentiated from other monoclonal antibodies acting on these pathways due to its distinct blocking of Type 2 receptor signaling without impairing Type 1 receptor signaling.”
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ASLN:
- ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
- ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
- Aslan Pharmaceuticals enters strategic licensing deal with Zenyaku Kogyo
- ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
- Is ASLN a Buy, Before Earnings?